# A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

Source: https://onco.cc/trials/nct05207670/  
OnCo record `nct05207670` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mosunetuzumab, Tocilizumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Genentech, Inc., active and no longer recruiting.

## Summary

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies is a phase 2 interventional study registered as NCT05207670 by Genentech, Inc., with 320 participants enrolled, started 2022-02-01 and due to reach its primary completion in 2027-07-31. Interventions recorded: Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab. Conditions listed: Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05207670
- Phase: 2
- Setting: An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies
- Sponsor: Genentech, Inc.
- Enrolled: 320

## Sources

- ClinicalTrials.gov NCT05207670: https://clinicaltrials.gov/study/NCT05207670

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Mosunetuzumab](https://onco.cc/drugs/mosunetuzumab/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct05207670.json